Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature

被引：26

作者：

Whitworth, Jenny M. ^{[1
]}

Alvarez, Ronald D. ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Div Gynecol Oncol, Birmingham, AL 35233 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2011年 / 11卷 / 06期

关键词：

gene therapy; interleukin; 12; ovarian cancer; recombinant; RECOMBINANT HUMAN INTERLEUKIN-12; CELL STIMULATORY FACTOR; NATURAL-KILLER-CELLS; INDEPENDENT PROGNOSTIC-FACTOR; PERIPHERAL-BLOOD LYMPHOCYTES; INTERFERON-GAMMA PRODUCTION; PHASE-I TRIAL; IFN-GAMMA; TUMOR-REGRESSION; INTRATUMORAL INJECTION;

D O I：

10.1517/14712598.2011.566854

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 [微生物学]; 090105 [作物生产系统与生态工程];

摘要：

Areas covered: This review examines the anti-tumor mechanism of action of IL-12 and the development of IL-12 as a potential therapeutic option in a variety of malignancies. It also reviews the immunogenicity of ovarian cancer and covers preclinical and clinical trials that have contributed to the advancement of IL-12 as a potential therapy for ovarian malignancy. The obstacles that researchers have overcome and currently face regarding the use of IL-12 in clinical ovarian cancer trials are also discussed. Expert opinion: IL-12, as a therapeutic modality, is mechanistically logical and shows great promise in preclinical trials. Further clinical studies are warranted to optimize the potential of IL-12 as a treatment strategy for ovarian cancer.

引用

页码：751 / 762

页数：12

共 108 条

[1]

LIPOSOMAL VACCINES - CLINICAL STATUS AND IMMUNOLOGICAL PRESENTATION FOR HUMORAL AND CELLULAR-IMMUNITY [J].